Use of Sacubitril/Valsartan in heart failure with reduced ejection fraction
WU Li-qiang1
FENG Hui-ting2
FENG Hui-juan1
1.Guangdong Hospital of Traditional Chinese Medicine,Guangzhou 510006, Guangdong2.The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou 510655,Guangdong, China
摘要：Background Angiotensin receptor and neprilysin inhibition (ARNI) has been shown to reduce cardiovascular mortality.However,there is a paucity of real-world data in the effects of ARNI in heart failure patients with reduced ejection fraction (HFrEF).Methods We included 225 consecutive HFrEF patients receiving combined sacubitril/valsartan administration and standard HF treatment (Group A) and 550 consecutive HFrEF patients receiving only the standard HF treatment (Group B) from January 2016 to January 2018.Primary outcome was death from cardiovascular causes or first unplanned hospitalization for HF.Results Thirty-three deaths or first unplanned hospitalization for HF occurred in Group A (14.7％) and 102 in Group B (22.7％) with 0.56 hazard ratio (HR),and 95％ confidence interval (CI,0.491-0.867;P=0.001) during a follow-up of 12 month.Moreover,escalation of sacubitril/valsartan (89 cases,39.6％) was associated with the best clinical outcomes (P＜0.001).But,the patients with severe hypotension and baseline SBP less than 100 mmHg in both groups had similar primary outcome.Conclusions Sacubitril/valsartan has beneficial effect on HFrEF patients and the effect enhances when higher dose is given.
机标关键词：
论文发表日期：2019-12-30
在线出版日期：2025-08-15（本平台首次上网日期，不代表文献的发表时间）
页数：6( 252-257 )
英文信息